PDCD1 and Miyoshi myopathy: Lenalidomide, an immunomodulatory drug, inhibits the expression of PD-1 in NK cells, helper T cells, and CTLs of MM patients and downregulates the expression of PD-L1 in myeloma cell lines and primary myeloma cells (20, 34).